Literature DB >> 11688464

Metanephric adenoma, nephrogenic rests, and Wilms' tumor: a histologic and immunophenotypic comparison.

T E Muir1, J C Cheville, D J Lager.   

Abstract

Metanephric adenoma (MA) is a renal tumor that is generally detected in adults and occasionally in children. These tumors usually behave in a benign fashion. Although the histogenesis of MA is unclear, a morphologic similarity to Wilms' tumor (WT) complex exists. Six cases of MA, five cases of childhood WT (CWT), two cases of adult WT (AWT), and four cases of treated MWT and/or nephrogenic rests (MWT/NR), with paraffin blocks available for use, were retrieved from the surgical pathology files of the Mayo Clinic. Clinical information was extracted from the medical record. Immunoperoxidase stains for WT1, AE1, CK7, CD57, CD56, and desmin were performed on paraffin sections from all cases. All six cases of MA were strongly and diffusely positive with antibodies to WT1 and CD57 and focally positive with antibodies to CK7. Three cases showed focal faint staining in <5% of the cells with keratin AE1. Stains for CD56 and desmin were negative. All seven cases of WT, including five CWT and two AWT, were strongly and diffusely positive with WT1 in the blastema and epithelium but showed only weak focal positivity in stromal cells. Six cases were diffusely positive for CD56 and one case showed focal positivity. Keratin AE1 was positive in one case of AWT and focally positive in the other AWT. The blastema of all cases of WT were negative for desmin, CK7, and CD57, although staining for keratin AE1, CD56, and CD57 was seen in maturing tubules of CWT cases. Of the five CWT cases, two had associated NR and two showed maturing WT after treatment. The areas of NR and maturing WT were histologically similar to MA and were composed of small tubules with uniform nuclei with no mitotic activity, scant cytoplasm, and focal calcifications. All four cases of maturing WT/NR were positive for WT1 and focally positive for CD57, CK7, and AE1. Stains for CD56 and desmin were negative except in foci of residual blastema, which stained for CD56 but lacked CD57 and CK7 staining. Five cases each of renal cell carcinoma, papillary renal cell carcinoma, and oncocytoma were negative for WT1. Two of five cases of chromophobe carcinoma showed very weak staining present in <10% of tumor nuclei. Metanephric adenoma is histogenetically related to WT and is morphologically and immunophenotypically identical to maturing WT and nephrogenic rests.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11688464     DOI: 10.1097/00000478-200110000-00010

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  18 in total

1.  Metanephric adenoma of the kidney: a clinicopathological and molecular study of two cases.

Authors:  Maximilian Burger; Kerstin Junker; Stefan Denzinger; Thomas Schubert; Robert Stoehr; Wolf-Ferdinand Wieland; Arndt Hartmann
Journal:  J Clin Pathol       Date:  2006-11-10       Impact factor: 3.411

2.  Novel clinicopathological and molecular characterization of metanephric adenoma: a study of 28 cases.

Authors:  Ying Ding; Cong Wang; Xuejie Li; Yangyang Jiang; Ping Mei; Wenbin Huang; Guoxin Song; Jinsong Wang; Guoqiang Ping; Ran Hu; Chen Miao; Xiao He; Gang Chen; Hai Li; Yan Zhu; Zhihong Zhang
Journal:  Diagn Pathol       Date:  2018-08-16       Impact factor: 2.644

3.  Differential diagnosis of renal tumors with tubulopapillary architecture in children and young adults: a case report and review of literature.

Authors:  Longwen Chen; Fang-Ming Deng; Jonathan Melamed; Ming Zhou
Journal:  Am J Clin Exp Urol       Date:  2014-10-02

4.  Cadherin 17 is a sensitive and specific marker for metanephric adenoma.

Authors:  Evgeny Yakirevich; Cristina Magi-Galluzzi; Zakaria Grada; Shaolei Lu; Murray B Resnick; Shamlal Mangray
Journal:  Am J Surg Pathol       Date:  2015-04       Impact factor: 6.394

5.  Immunohistochemical phenotype and molecular pathological characteristics of metanephric adenoma.

Authors:  Zhulei Sun; Shihai Kan; Leilei Zhang; Yan Zhang; Hong Jing; Gui Huang; Qichun Yu; Jiang Wu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

6.  Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastoma.

Authors:  Stephanie N Kinney; John N Eble; Ondrej Hes; Sean R Williamson; David J Grignon; Mingsheng Wang; Shaobo Zhang; Lee Ann Baldrige; Guido Martignoni; Matteo Brunelli; Lisha Wang; Eva Comperat; Rong Fan; Rodolfo Montironi; Gregory T MacLennan; Liang Cheng
Journal:  Mod Pathol       Date:  2015-08-07       Impact factor: 7.842

7.  Wilms Tumor: An Uncommon Entity in the Adult Patient.

Authors:  Fade Mahmoud; M Brandon Allen; Roni Cox; Rodney Davis
Journal:  Perm J       Date:  2016-03-21

8.  Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma.

Authors:  Aaron M Udager; Jincheng Pan; Martin J Magers; Ganesh S Palapattu; Todd M Morgan; Jeffrey S Montgomery; Alon Z Weizer; Khaled S Hafez; David C Miller; James S Wolf; Jonathan B McHugh; Arul M Chinnaiyan; Saravana M Dhanasekaran; Rohit Mehra
Journal:  Am J Surg Pathol       Date:  2015-04       Impact factor: 6.394

9.  ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study.

Authors:  James I Geller; Joseph G Pressey; Malcolm A Smith; Rachel A Kudgus; Mariana Cajaiba; Joel M Reid; David Hall; Donald A Barkauskas; Stephen D Voss; Steve Y Cho; Stacey L Berg; Jeffrey S Dome; Elizabeth Fox; Brenda J Weigel
Journal:  Cancer       Date:  2020-09-11       Impact factor: 6.860

10.  Composite tumor of metanephric adenoma and Wilms' tumor of the kidney: A case report and review of the literature.

Authors:  Pengcheng Zhu; Fei Yan; Zixuan Yang; Li Meng; Qilin Ao
Journal:  Oncol Lett       Date:  2013-01-22       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.